Strategic Partnership to Deliver US Based
Manufacturing Capacity for Novel Cell Therapy
KING OF
PRUSSIA, Pa., April 12,
2022 /PRNewswire/ --The Center for Breakthrough
Medicines (CBM) announced today a partnership with London-based Achilles Therapeutics plc
(NASDAQ: ACHL). The deal provides expanded cell therapy
manufacturing capabilities required to supply products for
Achilles' ongoing Phase I/IIa clinical trials in advanced non-small
cell lung cancer and metastatic or recurrent melanoma patients. CBM
is a contract development and manufacturing organization (CDMO)
dedicated to addressing the challenges associated with developing
and manufacturing advanced therapies. Achilles is a clinical-stage
biopharmaceutical company developing precision T-cell therapies to
treat solid tumors.
"We are bringing together two powerful, experienced cell therapy
organizations for the benefit of cancer patients," said
John Lee, Ph.D., Vice
President, Head of Cell Therapy, CBM. "We look forward to
mobilizing our world-class cell therapy capabilities, with our
first wave of cell therapy suites to enable Achilles to accelerate
the development of their flagship precision T cell product
candidate."
"Achilles is thrilled to partner with CBM given their
experience, capabilities, available cell therapy capacity and
strategic location. After opening our US headquarters in
Philadelphia, CBM's King of Prussia location was perfect for our
needs," said Edward Samuel,
Executive Vice President of Technical Operations at Achilles
Therapeutics. "The expertise of the CBM team, along with their
ability to provide on-demand, flexible access to autologous cell
therapy manufacturing GMP space was vital in our decision."
CBM will manufacture Achilles' precision T cell therapy for the
company's ongoing Phase I/IIa clinical trials in non-small cell
lung cancer and melanoma patients.
"Our ability to deliver customizable manufacturing solutions for
partners seeking autologous cell therapy production positions us
well with Achilles, and we are excited to support them on their
journey to bring desperately needed treatment options to cancer
patients," said Audrey Greenberg,
co-founder, CBM. "We employ the most sophisticated scheduling,
supply chain and inventory control systems integrated with
industry-leading comprehensive in-process testing, quality control,
and lot release programs in the industry. Achilles' goal to deliver
improved therapies to cancer patients also aligns with CBM's
mission and culture."
About The Center for Breakthrough Medicines (CBM)
CBM
is a purposefully built advanced therapy contract development and
manufacturing organization (CDMO) based in the heart of
Philadelphia's Cellicon Valley.
CBM offers pre-clinical through commercial manufacturing
capabilities including process development, plasmid DNA, viral
vector, cell therapy and a full suite of testing and analytical
capabilities. Through a single-source, end-to-end solution, CBM
accelerates time to market without compromising quality.
About Achilles Therapeutics
Achilles is a
clinical-stage biopharmaceutical company developing precision T
cell therapies targeting clonal neoantigens: protein markers unique
to the individual that are expressed on the surface of every cancer
cell. The Company has two ongoing Phase I/IIa trials, the CHIRON
trial in patients with advanced non-small cell lung cancer (NSCLC)
and the THETIS trial in patients with recurrent or metastatic
melanoma. Achilles uses DNA sequencing data from each patient,
together with its proprietary PELEUS™ bioinformatics platform,
to identify clonal neoantigens specific to that patient, and then
develop precision T cell-based product candidates specifically
targeting those clonal neoantigens.
View original
content:https://www.prnewswire.com/news-releases/the-center-for-breakthrough-medicines-cbm-strikes-multi-year-deal-with-uk-cell-therapy-powerhouse-301523555.html
SOURCE Center for Breakthrough Medicines